



**Supplementary Figure 5.** Cost-effectiveness acceptability curves. Iterations of the cost-effectiveness of empagliflozin versus placebo under different willingness to pay thresholds in models with and without adverse events. The red curve is the original model (Model 1) without accounting for adverse events; the green curve is the Model 2 accounting for adverse events